2. Candidate cell sources for regenerative medicine include:
1. ES cells, 2. Fetal cells, and 3. Adult stem cells.
3. Generation of bone tissue of desired sizes and shapes
Sheet-style biodegradable polymer, Hybridization of the PLGA
PLGA (200 um thick) as a scaffold with collagen microsponge
Collagen
microsponge
overlay the interstices of
the fabricated web-like
PLGA sheets
4. The cell-seeded sheets were rolled up
around a silicone rod,and cultivated
them in vivo for 4 weeks at the
subcutaneous tissue.
Cylinder-shaped bone
5. Bone knots
bone of more complex shapes
We can control bone shape completely
6. Generation of phalanges by the PLGA hybrid sheet
with marrow-derived mesenchymal cells.
phalange-like bone
Thumb of
the graduate student
7. In vitro and in vivo
chondrogenesis
2W
H
E
4
W
8W
Toluidine
blue
8. HE
Toluidine
blue
2W 4W 8W
x 200
Implantation of Cell X in pelleted micromass culture into the
nude mice
9. (%) 100 E-MSC100 (%) 100 E-MSC214
80
E-GFP(+)
Trop-I(+)
80
E-GFP(+)
oxytocin
Trop-I(+)
60
oxytocin
5-azaC
5-azaC
oxytocin
60
5-azaC
oxytocin
5-azaC
non
non
40
non
non
40
20
Endometrium 20
0
Feeder (-) Feeder (+) 0
Feeder (-) Feeder (+)
Primary culture
Limiting dilution E-MSC100
DAPI a actinine Cx43 Merge
E-MSC214
E-MSC100 p E-MSC214p
DAPI a actinine Cx43 Merge
11. 0
A B C H
100
Pipette
d
200
a
300
2sec 400
E-MSC100 1sec
b c
0 100 200 300 400 500 600
D E F I
5% %FS
site-a
Pipette
site-b
site-c
E-MSC214 2 sec 1 sec
site-d
time 1s
J
G 10
APD90 MDP AMP Rate Pacemaker(+) E-MSC100 E-MSC214
8
msec mV mV s n
E-MSC100 326±12 -55±1 56±7 0.9±0.1 3/17 6
%FS
E-MSC214 185 ±16 -48±3 56±3 2.4±0.2 16/22
4 n=9 n=10
Mean ± SE
APD; action potential duration, 2
MDP; Maximum diastolic potential, AMP; amplitude 0
Mean ± SE
14. SPIO Labeling
Fe
Fe Fe
Fe Fe Fe
Fe Fe
Fe Fe
Fe Fe
Fe
Fe Fe Fe
Fe
Fe
Fe Fe Fe Fe Fe
Fe Fe
Phagocytosis SPIO labeled cell
or
Pinocytosis
SPIO 効果 ; T2 短縮(信号低下)
•正常肝細胞は鉄コロイド
を貪食するので信号が低下
する
•貪食能のない病変は信号
が低下しないので白く浮き
出て見える
T2 強調 SPIO 造影 T2 強調
19. Distribution of GUSB GUSB-positive cells
activity in treated mouse brain
in the brain
2 or 8 wk after
Sakurai, Ohashi et al.
transplantation
Subventricl
e
Reduction of GAGs
contents after
transplantation
T-CS HA
600 * * 100 ** ** ** Cortex
90
500 80
400 * 70
60
300 50
40
200
nmol/hr/mg nmol/hr/mg
30
100 20
10
0 0
MPS VII
Normal Treated
VII
Normal Treated
Treated VII MPS MPS VII MPS MPS VII
MPS
VII
Normal
TreatedNormal TreatedNormal TreatedNormal Olfactory
Untreated Untreated Untreated MPS MPS VII MPS MPS VII MPS MPS VII
VII VII VII
4wk 8wk 16wk
Untreated Untreated Untreated
bulb
4wk 8wk 16wk Bar equals 200 mm
20. Improvement of cognitive function
Acquisition (d0-d5)
Target quadrant
Mean non-target
quadrants
Probe test
(d6)
Untreate Treated Normal
d MPS VII MPS VII